NIHON KAGAKU SANGYO (4094) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Cumulative results for Q3 of FY2026 showed increases in both revenue and profit, with profit progress against the full-year forecast also at a high level. Revenue was ¥206.1B (+6.8% YoY), Operating Income was ¥24.8B (+5.5%), Ordinary Income was ¥28.6B (+8.6%), and Net Income was ¥20.4B (+9.1%). Growth in revenue and profit in the core Chemicals Business drove overall company performance, while non-operating income, primarily dividends received and interest received, provided an additional boost to Ordinary Income. The Operating Income margin was 12.0%, representing a slight decline from the same period of the previous year, as costs somewhat offset the benefits of higher revenue.

Factors Affecting Performance

【Revenue】Revenue increased 6.8% YoY to ¥206.1B. Both businesses contributed to the revenue increase, with the Chemicals Business at ¥176.8B (+7.3% YoY) and the Building Materials Business at ¥29.3B (+4.2%). The revenue composition was 85.8% for the Chemicals Business and 14.2% for the Building Materials Business.

【Profit and Loss】Operating Income was ¥24.8B (+5.5%), slightly below the 6.8% revenue growth rate, and the Operating Income margin narrowed slightly year on year to 12.0%. Segment profit in the Chemicals Business increased to ¥27.9B (+8.8%), while segment profit in the Building Materials Business declined to ¥4.5B (-5.3%). In addition, adjustments for the Administration Division and other items expanded to ¥7.6B (¥6.8B in the previous year), causing the company-wide profit growth rate to fall below revenue growth. Ordinary Income increased 8.6% to ¥28.6B, outpacing Operating Income growth, driven by ¥4.3B in non-operating income, primarily including ¥2.4B in dividends received. Extraordinary gains and losses were both small, limiting their impact as temporary factors, and Net Income was ¥20.4B (+9.1%). In conclusion, the company achieved increases in both revenue and profit.

Segment Analysis

The Chemicals Business drove overall earnings growth, with revenue of ¥176.8B (+7.3% YoY), segment profit of ¥27.9B (+8.8%), and a profit margin of 15.8%. The Building Materials Business secured higher revenue of ¥29.3B (+4.2%), but segment profit declined to ¥4.5B (-5.3%), and its profit margin of 15.2% was close to that of the Chemicals Business, although profit growth lagged. After deducting ¥7.6B in adjustments for the Administration Division and other items from total segment profit of ¥32.3B, company-wide Operating Income was ¥24.8B. The increase in adjustments was one factor depressing the company-wide profit growth rate.

Key Financial Indicators

【Profitability】The Operating Income margin was 12.0% and the Net Income margin was 9.9%, calculated from a structure comprising a gross profit margin of 24.5% and an SG&A expense ratio of 12.5%. Operating Income growth of 5.5% versus revenue growth of 6.8% indicates somewhat weak operating leverage.【Cash Flow Quality】Because Operating Cash Flow data has not been disclosed, the cash backing of Net Income cannot be verified. However, DSO is estimated at approximately 102 days and CCC at approximately 133 days. Accounts receivable of ¥76.6B represents approximately 37.2% of revenue and is a point of attention in terms of capital efficiency.【Investment Efficiency】ROE was 4.1%. Asset efficiency relative to total assets of ¥585.7B is constrained by a substantial asset composition consisting of ¥124.3B in investment securities and ¥195.0B in cash and deposits.【Financial Soundness】The Equity Ratio was 84.0%, and current assets of ¥342.1B substantially exceeded current liabilities of ¥59.9B. Net assets of ¥491.8B against total liabilities of ¥93.9B indicate a conservative capital structure.

Cash Flow Analysis

As figures from the statement of cash flows have not been disclosed, funding trends are assessed based on changes in the balance sheet. Cash and deposits increased to ¥195.0B from ¥154.2B in the previous year, providing substantial coverage equivalent to approximately 3.3 times current liabilities of ¥59.9B. Meanwhile, accounts receivable and notes receivable increased to ¥76.6B from ¥69.5B in the previous year, accumulating at a pace exceeding revenue growth. This expansion in receivables suggests an elongation of the working capital cycle and indicates that cash generation from operating activities may not have fully kept pace with Net Income growth. Investment securities increased substantially to ¥124.3B from ¥88.5B in the previous year, suggesting that a portion of funds has been allocated to investment assets.

Earnings Quality

The current profit growth was generally based on recurring business earnings. Ordinary Income exceeded Operating Income by ¥3.8B, primarily due to ¥4.3B in non-operating income, centered on ¥2.4B in dividends received and ¥0.6B in interest received, representing approximately 2.1% of revenue and remaining limited in scale. Extraordinary gains and losses had a largely offsetting effect, consisting of a ¥0.1B gain on the sale of investment securities and a ¥0.4B loss on the disposal of fixed assets, resulting in a small impact on Net Income. Meanwhile, comprehensive income reached ¥44.8B, approximately 2.2 times Net Income of ¥20.4B. The difference was almost entirely attributable to ¥25.2B in valuation difference on investment securities. This divergence reflects a temporary valuation factor associated with market fluctuations and should be distinguished from the company’s recurring earnings power.

Earnings Forecast and Guidance

Progress against the full-year revenue forecast of ¥262.0B was 78.7%, exceeding the standard progress rate of 75% after nine months. Progress against the Operating Income forecast of ¥26.8B was 92.5%, while progress against the Ordinary Income forecast of ¥31.0B was 92.2% and progress against the Net Income forecast of ¥22.2B was 91.8%; all substantially exceeded standard progress. Although the full-year forecasts for Operating Income and Ordinary Income imply year-on-year declines (-6.3% and -3.5%, respectively), cumulative results through Q3 are already progressing above the previous year, suggesting that the assumptions for Q4 may be conservative.

Shareholder Returns

A dividend of ¥45 was paid in Q2, and the full-year forecast is ¥90 (assuming an interim dividend of ¥45 and a year-end dividend of ¥45). Based on cumulative dividends of ¥45 paid in Q2, the cumulative Payout Ratio was approximately 44.8% against Net Income of ¥20.4B, below the 60% benchmark. Based on the full-year forecast, the Payout Ratio will be approximately 78.9%, calculated as a dividend of ¥90 against forecast EPS of ¥114.08. No disclosure regarding share buybacks has been made, and this report evaluates only the Payout Ratio. The company’s substantial cash and deposits of ¥195.0B and low debt burden provide financial support for dividend payments.

Risk Factors

1. Prolonged collection period for accounts receivable: Accounts receivable and notes receivable were ¥76.6B, equivalent to approximately 37.2% of revenue, and DSO is estimated at approximately 102 days. A longer collection period could tie up working capital and widen the divergence between Operating Cash Flow and Net Income.

2. Deteriorating profitability in the Building Materials Business: Although the Building Materials Business secured higher revenue of ¥29.3B (+4.2% YoY), segment profit declined to ¥4.5B (-5.3%). If profit margins continue to decline despite continued revenue growth, this could weigh on company-wide profit.

3. Valuation fluctuation risk of investment securities: Investment securities totaled ¥124.3B, representing 21.2% of total assets, and were the primary driver of the difference between comprehensive income of ¥44.8B and Net Income of ¥20.4B. The capital structure is susceptible to fluctuations in net assets and comprehensive income due to changes in equity market conditions.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin exceed the industry median, placing the company’s profitability at a relatively high level within the industry.

Growth and Capital Efficiency

The revenue growth rate also exceeds the industry median, while remaining within the upper bound of the IQR (8.9%), placing the company in the upper tier of the industry.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Progress against the full-year forecast was high, at 92.5% for Operating Income and 91.8% for Net Income, substantially exceeding standard progress after nine months. Although the full-year forecasts for Operating Income and Ordinary Income imply year-on-year declines, cumulative results have already exceeded the previous year, making the relationship between the Q4 forecast and actual results a key point of focus.

2. The Operating Income margin was 12.0%, slightly narrower than in the same period of the previous year. Operating Income growth of 5.5% versus revenue growth of 6.8% indicates that costs partially offset the benefits of higher revenue. While the Chemicals Business drove profit growth, the Building Materials Business recorded higher revenue but lower profit, confirming changes in the earnings structure by business.

3. Ordinary Income and Net Income were affected by non-operating income and comprehensive income. In particular, comprehensive income of ¥44.8B reached approximately 2.2 times Net Income. This divergence resulted from market-related fluctuations attributable to valuation differences on investment securities and should be considered separately from the company’s recurring earnings power.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 earnings were solid, with revenue, operating income and net income all increasing year on year, although the full-year earnings target is already substantially captured and therefore leaves little room for a weak Q4. Revenue increased 6.8% year on year to ¥20.61bn. Operating income rose 5.5% to ¥2.48bn. Ordinary income increased 8.6% to ¥2.86bn, outpacing operating-income growth. Net income attributable to owners rose 9.1% to ¥2.04bn, or ¥104.78 per share. The gross margin was 24.5%, down approximately 29bp from 24.8% a year earlier. The operating margin was broadly stable at 12.0%, versus approximately 12.2% in the prior-year period. The net margin improved by roughly 20bp to 9.9%, supported by non-operating investment income. Dividend income of ¥237m represented a meaningful contributor to non-operating income of ¥434m. Consequently, ordinary income growth exceeded operating-income growth, indicating that below-the-line investment returns supplemented core operating performance. Small extraordinary items had a limited net negative effect: a ¥12m gain on securities sales was more than offset by a ¥36m loss on disposal of fixed assets. The effective tax rate was 28.1%, producing a normal 71.9% tax burden ratio. Comprehensive income reached ¥4.48bn, well above net income, primarily reflecting an increase in the valuation difference on securities. The balance sheet remains exceptionally liquid, with cash and deposits of ¥19.50bn and a current ratio of 570.6%. Investment securities increased 40.4% year on year to ¥12.43bn, increasing the importance of market-value movements to equity and comprehensive income. The Chemical Business remained the core business, contributing 85.8% of segment revenue and 86.2% of aggregate segment profit. Full-year forecast progress is ahead of the normal 75% Q3 pace for sales and earnings, suggesting that the company’s guidance embeds a sharply slower fourth quarter. The principal operational issue is working-capital efficiency, as the reported 102-day receivable period and 133-day cash conversion cycle are long for a manufacturer. Overall, the results show resilient core profitability, strong capital preservation and a favorable earnings progression, while collection-cycle discipline and reliance on investment-related income remain important monitoring points.

Profitability Analysis

The supplied annualized DuPont analysis gives ROE of 5.5%, decomposed into a 9.9% net profit margin, 0.469x asset turnover and 1.19x financial leverage. The principal constraint on return on equity is low financial leverage and modest asset turnover rather than weak profitability: the company maintains a very equity-heavy capital structure, with total equity of ¥49.18bn against total assets of ¥58.57bn. The annualized 9.9% net margin is close to the 10% high-quality profitability threshold, while the 12.0% EBIT margin is firmly within the 8-15% good operating-margin range. Gross margin compressed approximately 29bp year on year to 24.5%, indicating that input costs, sales mix or pricing absorbed part of the benefit of revenue growth. Operating margin was nevertheless broadly stable because SG&A rose about 5.8%, slower than the 6.8% increase in revenue. This modest favorable operating leverage partly offset gross-margin pressure. Net-margin expansion was driven more by the increase in non-operating income than by operating-margin expansion. Dividend income of ¥237m, equivalent to 9.6% of operating income, was the largest disclosed component of non-operating income and enhances reported earnings but is distinct from manufacturing operations. The five-factor DuPont tax burden of 0.719 is normal, while the interest burden of 1.144 reflects net interest and investment income exceeding the very small financing cost. Interest coverage of 2,458.33x confirms that debt servicing is immaterial to earnings. Chemical Business segment profit increased 8.8% to ¥2.79bn, faster than its 7.3% revenue growth, implying margin expansion. Building Materials segment revenue increased 4.2% to ¥2.93bn, but segment profit declined 5.3% to ¥447m, implying margin compression. Segment-level profit margins were 15.8% for Chemical Business and 15.2% for Building Materials, before corporate-cost allocation. Corporate and head-office costs increased 10.6% to ¥755m, faster than consolidated sales, and absorbed part of segment-level profit growth. The annualized ROE of 5.5% remains below the 8% benchmark, so higher operating returns or more active capital allocation would be required to improve shareholder-return efficiency.

Growth Assessment

Revenue growth was led by the Chemical Business, where sales increased ¥1.20bn year on year to ¥17.68bn. This segment accounted for approximately 86% of consolidated revenue and is clearly the core business. Its segment-profit growth of ¥226m exceeded its sales increase on a percentage basis, supporting the quality of its expansion. Building Materials added ¥119m of revenue, but its ¥25m decline in segment profit signals weaker incremental profitability and warrants attention. Consolidated operating income grew more slowly than revenue because gross-margin compression and higher corporate costs offset the improvement in Chemical Business. Ordinary and net income grew faster than operating income, supported by higher non-operating income, particularly dividends received. The full-year sales forecast is ¥26.20bn, making Q3 cumulative progress 78.7%, 3.7 percentage points above the standard 75% Q3 pace. Operating-income progress is 92.5% against the ¥2.68bn forecast, 17.5 percentage points above the standard pace. Ordinary-income progress is 92.2% against the ¥3.10bn forecast, also 17.2 percentage points above the standard pace. Net-income progress is 91.8% against the ¥2.22bn forecast, 16.8 percentage points above standard pace. The forecast therefore implies Q4 revenue of ¥5.59bn, operating income of only ¥202m, ordinary income of ¥241m and net income of ¥181m. This implied Q4 operating margin of approximately 3.6% is materially below the Q3 cumulative 12.0% margin. The divergence may reflect seasonality, planned costs, conservative guidance, or a more challenging expected fourth-quarter sales mix. Full-year guidance calls for 3.0% sales growth but 6.3% and 3.5% declines in operating and ordinary income, respectively, versus the preceding full year, underlining management’s caution on the exit rate. The absence of reported segment impairment or goodwill-related charges supports the current period’s operating-profit quality. Sustainability of reported net-income growth nonetheless depends on maintaining core Chemical Business margins and on the stability of investment-income contributions.

Financial Health

Financial health is very strong. The current ratio is 570.6% and the quick ratio is 541.5%, substantially above conventional liquidity thresholds. Current assets of ¥34.21bn exceed current liabilities of ¥5.99bn by ¥28.21bn. Cash and deposits of ¥19.50bn alone are more than 3.2 times current liabilities. Debt-to-equity is only 0.19x, well below the 1.0x conservative-capital-structure benchmark and far from the 2.0x warning threshold. Total liabilities represent only 16.0% of total assets, while owners' equity represents approximately 84.0%. There is no evident short-term funding mismatch because liquid current assets substantially exceed current obligations. Trade payables of ¥3.30bn and electronic payables of ¥530m are supported by cash, receivables and operating working capital. Interest expense was just ¥1m, consistent with very limited financial leverage. Cash and deposits increased ¥4.08bn, or 26.5% year on year, to ¥19.50bn, strengthening financial flexibility. Investment securities increased ¥3.58bn, or 40.4%, to ¥12.43bn and now account for 21.2% of total assets. This portfolio expansion, together with a ¥2.52bn positive valuation difference on securities in OCI, was a major contributor to the ¥2.44bn increase in other comprehensive income. Equity therefore benefits from substantial financial-asset valuation reserves, but is correspondingly more exposed to equity-market fluctuations. Deferred tax liabilities increased to ¥2.80bn from ¥1.63bn, consistent with unrealized gains embedded in the securities portfolio. Asset retirement obligations were ¥41m, equivalent to roughly 0.4% of total liabilities, which is low relative to the chemical-industry environmental-liability benchmark. Intangible assets were only ¥124m, or 0.2% of assets, and segment disclosures report no goodwill or impairment charges, limiting acquisition-accounting and impairment risk.

Notable B/S Changes

Investment securities: +¥3.58bn (+40.4%) to ¥12.43bn — portfolio assets now represent 21.2% of total assets; valuation movements materially affect OCI, equity and investment-income exposure. Cash and deposits: +¥4.08bn (+26.5%) to ¥19.50bn — materially strengthens liquidity and dividend/funding capacity. Total equity: +¥2.70bn (+5.8%) to ¥49.18bn — supported by retained earnings and a substantial increase in accumulated other comprehensive income. Accumulated other comprehensive income: +¥2.44bn to ¥7.05bn — primarily associated with positive securities valuation movements, increasing sensitivity of book value to financial-market volatility. Deferred tax liabilities: +¥1.17bn (+72.2%) to ¥2.80bn — consistent with increased unrealized gains on investment securities and reinforces the link between equity changes and portfolio valuations. Electronic monetary claims: +¥0.93bn (+98.2%) to ¥1.87bn — adds to customer-related funding tied up in receivables and is relevant to the elevated collection cycle.

Cash Flow Quality

The reported working-capital indicators identify a cash-conversion concern despite the company’s strong balance-sheet liquidity. Reported annualized receivable days of 102 exceed the 60-day warning threshold. This is the root cause of the HIGH_RECEIVABLE_DAYS quality alert: a long collection period ties up capital in customer credit and increases sensitivity to delayed payments or credit losses. Trade receivables were ¥7.66bn and electronic monetary claims were ¥1.87bn, demonstrating that customer-related claims are material relative to quarterly cumulative sales. The context is that the allowance for doubtful accounts is small at ¥1m, so the issue is principally collection speed rather than a currently recognized credit-loss charge. The impact is lower working-capital efficiency and potentially weaker conversion of accounting profit into cash during periods of sales growth. The 133-day reported annualized cash conversion cycle also exceeds the 120-day warning threshold. This LONG_CCC alert reflects that the period required to convert production and sales activity into cash is extended for a manufacturing company. Such a long cycle raises the amount of internally funded working capital required as revenue grows and can reduce cash flexibility if customer collections slow. Trade payables of ¥3.30bn and electronic payables of ¥530m provide some supplier financing, but do not fully offset the long receivable cycle. Inventory composition includes ¥1.92bn of raw materials, ¥1.42bn of work in process and ¥1.75bn of finished goods, making production and inventory management relevant to the cash cycle. The quality impact is mitigated by ¥19.50bn of cash and deposits and low leverage, which provide a substantial liquidity buffer. The modest net extraordinary loss of approximately ¥24m, or about 1.2% of net income, does not materially distort earnings. Dividend income of ¥237m supports profit but is investment-derived rather than generated by the operating cash cycle. Management’s collection terms, customer mix, electronic-receivable growth and inventory discipline are therefore the most relevant indicators for future cash-conversion quality.

Dividend Sustainability

The company paid an interim Q2 dividend of ¥45 per share and forecasts a full-year dividend of ¥90 per share. The calculated Q3 cumulative dividend payout ratio is 44.8%, which is within the below-60% sustainability benchmark. Based on the full-year EPS forecast of ¥114.08, the planned ¥90 annual dividend implies a prospective dividend payout ratio of approximately 78.9%. This prospective ratio is above the conservative 60% benchmark but remains below 100%, so it is supported by forecast earnings rather than requiring a distribution in excess of profit. Q3 cumulative EPS of ¥104.78 has already reached 91.8% of forecast full-year EPS, providing substantial near-term earnings coverage for the planned distribution. Retained earnings of ¥41.17bn and cash and deposits of ¥19.50bn provide a very large balance-sheet buffer relative to the expected cash dividend. The low 0.19x debt-to-equity ratio and immaterial interest burden further support financial capacity for dividends. Dividend sustainability is therefore primarily linked to the durability of earnings rather than liquidity or refinancing risk. The main caveat is that the implied Q4 profit contribution is small and a portion of Q3 ordinary income is supported by dividend income from investments. No share repurchase amount is provided; accordingly, the analysis is confined to the dividend payout ratio rather than a total return ratio. The full-year dividend policy appears financially supportable, while maintaining the projected payout ratio would require ongoing operating profitability and stable investment income.

Risk Assessment

Business risks include Chemical Business concentration: the core Chemical Business generates about 85.8% of revenue and 86.2% of aggregate segment profit, making consolidated results sensitive to demand, pricing and cost conditions in this segment., Building Materials profitability: segment profit declined 5.3% despite 4.2% revenue growth, indicating margin pressure that could persist if pricing, construction demand or input costs remain unfavorable., Manufacturing cost and supply-chain exposure: the Q3 gross-margin decline of about 29bp indicates sensitivity to raw-material, energy, logistics and product-mix movements., Working-capital execution: reported annualized DSO of 102 days and a 133-day cash conversion cycle elevate exposure to slower customer collections and higher funding needs during growth phases., Chemical-industry regulatory and environmental risk: changes in environmental regulations, remediation obligations, product stewardship requirements or plant-safety standards could raise operating and compliance costs..

Financial risks include Investment-portfolio valuation sensitivity: investment securities of ¥12.43bn equal 21.2% of assets, and the ¥2.52bn positive securities valuation movement in OCI demonstrates that equity is exposed to market-price reversals., Investment-income reliance: dividend income of ¥237m was 9.6% of operating income and helped ordinary-income growth exceed operating-income growth; portfolio income may be less controllable than operating earnings., Long receivable cycle: customer-related claims are sizeable, and an extended collection period can pressure cash conversion even though current liquidity is strong., Deferred-tax-liability exposure: deferred tax liabilities of ¥2.80bn are associated with unrealized valuation gains and may fluctuate as investment-security values change..

Key concerns include Highest priority: address the 102-day receivable period and 133-day cash conversion cycle, because both reduce capital efficiency and could weaken cash realization if trading conditions deteriorate., High impact but lower immediate probability: a material correction in listed investment values could reverse part of the OCI-driven increase in equity and comprehensive income., Moderate priority: the full-year forecast implies a sharply lower Q4 operating margin of approximately 3.6%, so the causes of expected fourth-quarter weakness are important for assessing the earnings trajectory., Moderate priority: Building Materials margin compression and the 10.6% increase in corporate costs require monitoring because they offset strong Chemical Business performance..

Investment Implications

Key takeaways include Core operating performance was positive: Q3 cumulative revenue rose 6.8%, operating income rose 5.5%, and Chemical Business segment profit rose 8.8%., Profitability is good at the operating level, with a 12.0% operating margin, but the annualized 5.5% ROE remains below the 8% benchmark because of modest asset turnover and a highly equity-funded balance sheet., Balance-sheet resilience is exceptional, supported by ¥19.50bn of cash, a 570.6% current ratio and 0.19x debt-to-equity., Full-year forecast progress is unusually advanced, with 92.5% operating-income progress by Q3, implying a conservative forecast or a significantly weaker fourth-quarter earnings profile., Investment securities and their valuation gains are material to equity and comprehensive income, increasing financial-market sensitivity., The interim dividend payout ratio is moderate, while the forecast full-year payout ratio of approximately 78.9% is more demanding but remains covered by projected EPS..

Metrics to watch include Chemical Business revenue growth and segment-profit margin, Building Materials segment-profit recovery, Q4 operating margin versus the approximately 3.6% margin implied by full-year guidance, Annualized DSO of 102 days and annualized cash conversion cycle of 133 days, Cash and electronic receivables relative to sales growth, Investment-security balance, valuation difference on securities and related OCI volatility, Dividend income contribution relative to operating income, Full-year dividend payout ratio versus forecast EPS.

Regarding relative positioning, The company is positioned as a conservatively financed, liquid specialty manufacturing business with good operating margins and limited acquisition-accounting risk. Its relative strengths are capital resilience, negligible interest burden and a strong Chemical Business franchise; its weaker relative features are sub-benchmark annualized ROE, slow working-capital conversion and meaningful exposure of equity and non-operating profit to investment assets.